SMARCD3 Antibody

What is SMARCD3 and why is it important in cancer research?

SMARCD3 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily D, member 3) is a subunit of the SWI/SNF chromatin remodeling complex. This protein has gained significant research interest due to its potential role as a tumor suppressor in various cancers. Evidence indicates that SMARCD3 is downregulated in malignant breast tissue compared to normal breast tissue, suggesting a tumor suppressor function. Notably, expression analysis across multiple patient cohorts has demonstrated significant downregulation of SMARCD3 in breast cancer relative to normal breast tissue . This downregulation appears to occur not only through mutations and copy number loss but potentially through transcriptional inactivation mechanisms such as promoter methylation . The importance of SMARCD3 in cancer research extends to its prognostic value, as low SMARCD3 expression correlates with worse patient outcomes - patients with unaltered SMARCD3 show an average survival extension of 673 days (1.9 years) compared to patients with low SMARCD3 expression .

What are the recommended protocols for SMARCD3 immunohistochemistry (IHC) staining?

For effective SMARCD3 immunohistochemical staining, researchers should follow these methodological steps based on validated protocols:

• Perform antigen retrieval using a standardized system such as Ventana Discovery ULTRA Staining module with Discovery CC1 for approximately 32 minutes.

• Apply primary antibody staining using anti-SMARCD3 antibodies (such as Abcam ab1711075) with appropriate antibody dilution buffer for 36 minutes at 36°C.

• For secondary immunostaining, use an anti-rabbit horseradish peroxidase conjugated antibody.

• Visualize immune complexes using diaminobenzidine tetrahydrochloride.

• Counter-stain with hematoxylin II for approximately 8 minutes.

• For scoring, evaluate nuclear intensity of SMARCD3 staining under pathologist guidance, categorizing as negative (-), weak (+), moderate (++), or strong (+++) .

This protocol has been successfully employed in breast cancer tissue microarray analysis and should be optimized for specific experimental conditions and tissue types.

How can I validate the specificity of SMARCD3 antibodies for my experiments?

Validating SMARCD3 antibody specificity is crucial for accurate experimental results. A recommended multi-step validation approach includes:

• Positive and negative control tissues: Use tissues known to express SMARCD3 (such as normal breast luminal cells) as positive controls, and tissues with low or no expression as negative controls. Research has shown strong nuclear staining in luminal cells of normal acini, reminiscent of estrogen receptor staining .

• Knockdown validation: Implement shRNA-mediated SMARCD3 knockdown in appropriate cell lines and confirm reduced antibody signal through Western blotting and/or qRT-PCR. This approach has been documented in studies involving MDA-MB-231, MDA-MB-468, and HeLa cell lines .

• Antibody optimization: Prior to experimental use, optimize antibody concentration and incubation conditions using serial dilutions and varying incubation times.

• Cross-reactivity testing: Ensure the antibody doesn't cross-react with other SMARCD family members (SMARCD1, SMARCD2) by comparing staining patterns in tissues or cell lines with known differential expression of these proteins. Research has demonstrated that expression of the three isoforms is not correlated either positively or negatively .

• Multiple antibody comparison: When possible, validate results using multiple antibodies targeting different epitopes of SMARCD3.

How does SMARCD3 expression correlate with hormone receptor status in breast cancer, and what implications does this have for antibody-based detection methods?

SMARCD3 expression exhibits significant correlation with hormone receptor status in breast cancer, with important implications for antibody-based detection approaches. Immunohistochemical analysis has revealed that SMARCD3 protein levels are significantly associated with the IHC status of estrogen receptor (ER) and progesterone receptor (PR) (p<0.001) . Specifically, moderate to strong SMARCD3 expression positively correlates with ER expression and strong PR signaling .

• The potential influence of hormone receptor status on SMARCD3 expression levels.

• The need for appropriate controls stratified by hormone receptor status.

• Possible differences in SMARCD3 localization or epitope accessibility based on hormone receptor interactions.

These correlations suggest that SMARCD3 antibody staining should be interpreted within the context of the tumor's hormone receptor profile, particularly in ER+/PR+ breast cancers, where SMARCD3 may have specific functional relevance.

What methodological approaches should be used when studying SMARCD3's role in cell cycle progression using antibody-based techniques?

Investigating SMARCD3's role in cell cycle progression requires sophisticated antibody-based methodological approaches:

• Cell cycle synchronization and analysis: Use flow cytometry with PI staining for DNA content analysis in conjunction with SMARCD3 antibody staining. Research has shown that SMARCD3 depletion leads to modest G1 accumulation and decreased S phase entry .

• Dual immunofluorescence: Combine SMARCD3 antibody with antibodies against cell cycle markers (cyclin-dependent kinases, cyclins) to visualize co-localization during different cell cycle phases.

• FUCCI system implementation: Utilize the Fluorescent Ubiquitination-based Cell Cycle Indicator (FUCCI) system with live-cell imaging to investigate single cell behavior following SMARCD3 manipulation. Studies have demonstrated that individual phases of the cell cycle are longer in SMARCD3-depleted cells than in control cells .

• EdU incorporation assays: Combine with SMARCD3 antibody staining to specifically analyze DNA synthesis in S-phase cells with varying SMARCD3 expression.

• Western blotting for checkpoint proteins: Use SMARCD3 antibody alongside antibodies for cell cycle checkpoint proteins like p21. Research has demonstrated strong accumulation of p21 in response to SMARCD3 depletion .

• Proximity ligation assay (PLA): Apply PLA using antibodies against SMARCD3 and cell cycle regulatory proteins to detect physical interactions during different cell cycle phases.

These approaches should be tailored based on the specific research question and cell type, recognizing that SMARCD3 impacts on the cell cycle may vary between cancer types.

What are the recommended experimental designs for investigating SMARCD3's role in DNA damage response using antibody-based detection?

Given SMARCD3's correlation with homologous recombination deficiency (HRD) markers, researchers investigating its role in DNA damage response should consider these experimental approaches:

• Homologous recombination assay series:

  • Analyze correlation between SMARCD3 expression and established HRD markers using antibody-based detection.

  • Compare samples with low versus high SMARCD3 expression for:

    • Number of telomeric allelic imbalances (NtAI)

    • Large-scale state transitions (LST)

    • Number of genomic segments with Loss Of Heterozygozity (HRD-LOH)

    • Total HRD score (sum of individual markers)

  Research has demonstrated that these HRD markers and total HRD score are significantly higher in SMARCD3-low than in SMARCD3-high ER+ samples .

• Immunofluorescence co-localization: Use SMARCD3 antibody in combination with antibodies against DNA damage markers (γH2AX, 53BP1, RAD51) following induced DNA damage.

• Chromatin immunoprecipitation (ChIP): Apply SMARCD3 antibody in ChIP assays to identify genomic regions where SMARCD3 binds following DNA damage.

• Proximity ligation assay: Implement PLA using antibodies against SMARCD3 and DNA repair proteins to detect physical interactions during the DNA damage response.

• CRISPR-Cas9 genetic knockout validation: Compare antibody-based detection methods in wild-type versus SMARCD3-knockout cells to confirm specificity and validate functional observations.

When designing these experiments, consider the direct correlation observed between SMARCD3 expression and the Homology Directed Repair (HDR) signature , suggesting a mechanistic link between SMARCD3 and DNA repair pathways.

How does SMARCD3 expression pattern differ between pancreatic and breast cancer tissues, and what implications does this have for antibody selection?

SMARCD3 exhibits distinct expression patterns in pancreatic versus breast cancer tissues, necessitating tailored antibody selection approaches:

In pancreatic tissues, SMARCD3 shows a progressive expression pattern, with:

• Rare expression in benign inflamed tissue (pancreatitis)

• Increased nuclear SMARCD3+ epithelial cells in PanIN (Pancreatic Intraepithelial Neoplasia)

• Further elevated expression in PDAC (Pancreatic Ductal Adenocarcinoma)

• Enrichment within PROM1+ (CD133+) and MSI2+ tumor cells in primary human PDAC tumors (1.5-fold and 3-fold, respectively)

• Association with KRAS mutation status (expressed in 58% of KRAS wildtype tumors and only 17% of KRAS mutant tumors)

In breast tissues:

• Strong nuclear staining in luminal cells of normal acini

• Significantly reduced expression in malignant breast tissue compared to normal tissue (3.8-fold decrease)

• Variable nuclear intensity across patient samples

• Strong correlation with hormone receptor status

These differential expression patterns have important implications for antibody selection:

• Different epitope accessibility may require distinct antibody clones optimized for each tissue type

• Background staining profiles differ between pancreatic and breast tissues, potentially requiring different blocking strategies

• Different subcellular localizations may necessitate specialized fixation and permeabilization protocols

• Validation controls should be tissue-specific, using appropriate positive and negative controls for each cancer type

What are the optimal methodologies for detecting SMARCD3 in patient-derived xenograft (PDX) models?

For optimal detection of SMARCD3 in PDX models, researchers should implement a comprehensive methodological approach:

• Tissue processing optimization:

  • Fresh PDX tumor tissue should be fixed in 10% neutral buffered formalin for 24 hours

  • Process tissues through graduated alcohols and xylene

  • Embed in paraffin and section at 4-5μm thickness for optimal antibody penetration

• Dissociation and flow cytometry protocol:

  • Dissociate PDX tumors into single-cell suspensions using enzymatic digestion

  • Perform multiparameter flow cytometry using SMARCD3 antibody in combination with:

    • EpCAM antibody to identify epithelial tumor cells

    • CD133 antibody to identify stem cell populations

  • This approach allows quantification of SMARCD3 expression in specific cellular subpopulations

• Lentiviral transduction assessment:

  • For functional studies, implement GFP-tagged lentiviral shRNA targeting SMARCD3

  • Monitor both the frequency and total number of GFP+EpCAM+ tumor cells

  • Evaluate the CD133+ stem cell population within the GFP+EpCAM+ tumor fraction

• Comparative marker analysis:

  • When assessing SMARCD3 knockdown effects in PDX models, researchers should analyze:

    • Total tumor cells (EpCAM+)

    • Stem cell populations (CD133+)

    • Relevant signaling pathway components

Research has demonstrated that knockdown of SMARCD3 in PDX tumors can reduce the frequency and total number of GFP+EpCAM+ tumor cells by 2-50 fold, with even more pronounced effects (up to 100-fold reduction) in CD133+ stem cell populations .

How can I optimize Western blotting protocols for SMARCD3 detection in various cell lines?

For optimal Western blotting detection of SMARCD3 across different cell lines, researchers should implement these methodological refinements:

• Cell line-specific protein extraction:

  • For cell lines with high SMARCD3 expression (based on research showing variable expression across cell types), use standard RIPA buffer

  • For cell lines with lower SMARCD3 expression, use more stringent lysis buffers containing higher detergent concentrations or nuclear extraction protocols to concentrate the nuclear protein fraction

• Loading control selection:

  • Given SMARCD3's nuclear localization, use nuclear-specific loading controls (e.g., Lamin B1, Histone H3) rather than cytoplasmic markers

  • Consider normalizing to BRG1 (SMARCA4) levels in addition to standard loading controls, as SMARCD3 functions within the SWI/SNF complex

• Protein transfer optimization:

  • SMARCD3 has a molecular weight of approximately 55 kDa

  • Use PVDF membranes with 0.45 μm pore size

  • Optimize transfer conditions (voltage, time, buffer composition) based on the molecular weight

• Antibody incubation parameters:

  • Test both monoclonal and polyclonal antibodies to identify optimal specificity

  • Implement overnight primary antibody incubation at 4°C at optimized dilutions

  • Use 5% BSA rather than milk for blocking and antibody dilution to reduce background

• Signal enhancement strategies:

  • For cell lines with low SMARCD3 expression, consider using enhanced chemiluminescence (ECL) substrates with higher sensitivity

  • Implement signal accumulation mode on digital imaging systems for weak signals

• Validation controls:

  • Include positive controls (cell lines with known high SMARCD3 expression)

  • Include SMARCD3 knockdown samples as negative controls, as validated in studies using MDA-MB-231, MDA-MB-468, and HeLa cell lines

What considerations should be made when using SMARCD3 antibodies for chromatin immunoprecipitation (ChIP) experiments?

When implementing SMARCD3 antibodies for ChIP experiments, researchers should address these critical methodological considerations:

• Antibody selection criteria:

  • Choose antibodies validated specifically for ChIP applications

  • Select antibodies recognizing epitopes not masked by protein-DNA interactions

  • Consider ChIP-grade antibodies targeting different epitopes to validate findings

• Crosslinking optimization:

  • Since SMARCD3 is part of a chromatin remodeling complex, standard formaldehyde crosslinking (1%) may be insufficient

  • Test dual crosslinking approaches incorporating both formaldehyde and protein-protein crosslinkers like DSG (disuccinimidyl glutarate) to better capture protein complex interactions

• Sonication parameters:

  • Optimize sonication conditions to achieve fragments of 200-500bp

  • Validate sonication efficiency across different cell types, as chromatin accessibility varies

  • Consider using enzymatic fragmentation alternatives for challenging samples

• Immunoprecipitation controls:

  • Include IgG negative controls from the same species as the SMARCD3 antibody

  • Include positive controls targeting known SWI/SNF complex components (e.g., SMARCA4/BRG1)

  • Consider performing sequential ChIP (Re-ChIP) with SMARCD3 and other SWI/SNF components to identify co-occupied regions

• Washing stringency balance:

  • Implement a graduated washing strategy with increasing stringency

  • Optimize salt concentrations to reduce non-specific binding while maintaining true interactions

• Data validation approaches:

  • Confirm enrichment at expected genomic loci (regulatory regions)

  • Validate findings using orthogonal approaches like CUT&RUN

  • Consider validation through proximity ligation assay (PLA) to confirm SMARCD3 interactions with other transcription factors at specific genomic loci

• Analysis considerations:

  • When analyzing ChIP-seq data, account for SMARCD3's potential cell cycle-dependent binding patterns

  • Correlate binding sites with expression data to identify functional regulatory relationships

How can I design experiments to investigate the role of SMARCD3 in resistance to cancer therapies?

Given SMARCD3's significant prognostic implications and its association with therapy-resistant cell populations, researchers can implement these strategic experimental designs to investigate its role in therapy resistance:

• Patient-derived models with defined SMARCD3 status:

  • Establish PDX models from tumors with varying SMARCD3 expression levels

  • Subject these models to standard therapeutic regimens to correlate SMARCD3 expression with treatment response

  • Analyze CD133+ therapy-resistant stem cell populations in relation to SMARCD3 expression

• Isogenic cell line generation:

  • Create isogenic cell line pairs with SMARCD3 knockdown or overexpression

  • Test differential sensitivity to standard chemotherapeutics, targeted therapies, and radiotherapy

  • Evaluate molecular mechanisms of resistance through transcriptomic and proteomic analyses

• Cell cycle checkpoint modulation:

  • Given SMARCD3's impact on cell cycle progression and p21 expression , design studies comparing the efficacy of checkpoint inhibitors in SMARCD3-high versus SMARCD3-low contexts

  • Analyze how SMARCD3 status affects DNA damage response and repair following genotoxic therapies

• Dormancy and recurrence models:

  • Develop long-term in vitro and in vivo models to study the role of SMARCD3 in therapy-induced dormancy

  • Based on the observation that low-SMARCD3 expression predicts poor response to standard care , analyze how SMARCD3 deficiency might lead to dormancy and delayed cell cycle re-entry

• Combinatorial therapy screening:

  • Perform high-throughput drug screening to identify compounds that specifically sensitize SMARCD3-low tumors

  • Test rational drug combinations that target pathways dysregulated by SMARCD3 deficiency

• Hormone therapy resistance investigation:

  • Given SMARCD3's correlation with hormone receptor status , design experiments to determine if SMARCD3 loss contributes to hormone therapy resistance in ER+ breast cancers

  • Compare the efficacy of hormone therapies in patient-derived organoids with varying SMARCD3 expression levels

Research has shown that patients with low SMARCD3 expression might benefit more from aggressive or personalized treatments rather than standard care , making this investigation particularly relevant for clinical translation.

What are the most effective antibody-based methods for studying SMARCD3 interactions with other SWI/SNF complex components?

To effectively investigate SMARCD3 interactions with other SWI/SNF complex components, researchers should implement these advanced antibody-based methodologies:

• Proximity Ligation Assay (PLA):

  • Utilize antibodies against SMARCD3 and other SWI/SNF components (FOXA1, SMARCA4/BRG1)

  • Positive PLA signals (red) in nuclei (DAPI, blue) indicate protein-protein interactions at distances <40nm

  • This approach has been successfully used to demonstrate interactions between SMARCD3 and other chromatin remodeling components

• Co-immunoprecipitation with specialized conditions:

  • Use nuclear extracts prepared with specialized buffers that preserve complex integrity

  • Implement crosslinking approaches before immunoprecipitation to capture transient interactions

  • Perform reciprocal co-IPs using antibodies against different complex components

  • Analyze results using Western blotting or mass spectrometry for comprehensive interaction profiling

• ChIP-sequential immunoprecipitation (ChIP-reChIP):

  • Perform initial ChIP with SMARCD3 antibody

  • Re-immunoprecipitate using antibodies against other SWI/SNF components

  • This approach identifies genomic regions co-occupied by SMARCD3 and other complex members

• Immunofluorescence co-localization with super-resolution microscopy:

  • Implement multi-color immunofluorescence with antibodies against SMARCD3 and other SWI/SNF components

  • Analyze co-localization using super-resolution techniques (STORM, STED) to achieve nanometer-scale resolution

  • Quantify co-localization coefficients across different cell cycle stages and treatment conditions

• FRET (Förster Resonance Energy Transfer) analysis:

  • Label primary antibodies against SMARCD3 and interacting partners with appropriate FRET pairs

  • Measure energy transfer as an indicator of protein proximity

  • This approach provides spatial information about protein interactions in their native cellular context

• Bioluminescence Resonance Energy Transfer (BRET):

  • As an alternative to antibody-based approaches, use BRET with tagged SMARCD3 and potential interaction partners

  • Validate findings using antibody-based methods in endogenous contexts

These methodologies should be implemented with appropriate controls, including non-interacting proteins and mutant versions of SMARCD3 with disrupted interaction domains.